Literature DB >> 22568586

Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: a cross-sectional study.

Konstantina Apostolopoulou1, Heike E Künzel, Sabine Gerum, Katrin Merkle, Sebastian Schulz, Evelyn Fischer, Anna Pallauf, Volker Brand, Martin Bidlingmaier, Stephan Endres, Felix Beuschlein, Martin Reincke.   

Abstract

OBJECTIVE: The renin-angiotensin-aldosterone-system (RAAS) has gained increasing attention in the investigation of the pathogenesis of depression. Primary hyperaldosteronism (PA) is associated with a marked aldosterone excess. Prior studies on PA describe an increased prevalence of anxiety and sub-threshold depressive symptoms in these patients.
METHODS: In a cross-sectional exploratory study we investigated 132 patients with PA. Twenty-seven patients were studied before initiation of specific treatment (U = untreated), 56 were studied 5.4 years after initiation of mineralocorticoid antagonist treatment (MRA) and 49 patients were studied 4.3 years after unilateral adrenalectomy (ADX). GAD-7 and PHQD self-rating questionnaires were used to assess symptoms for anxiety and depression.
RESULTS: No significant difference was found between the three investigated groups. A higher prevalence for depression and anxiety compared to the normal population was found. Women of all groups had higher mean values compared to men, for depression in untreated patients this difference was found to be significant. Correlations between the psychopathology and hormones were only found for renin. Plasma renin concentration correlated significantly with anxious symptoms of untreated females.
CONCLUSIONS: This study supports the RAAS to be involved in the pathogenesis of depression as patients with PA seem to be more depressive and anxious compared to the normal population. Gender differences in the regulation of the RAAS seem to be apparent, as females were more affected by the dysregulation than males.

Entities:  

Mesh:

Year:  2012        PMID: 22568586     DOI: 10.3109/15622975.2012.665480

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  11 in total

Review 1.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

2.  Misdiagnosis of a hidden cause of hypertension: a case report.

Authors:  Andrés de Lima; Farah El-Sharkawy; Carol Nieroda; Armando Sardi
Journal:  Br J Gen Pract       Date:  2017-12       Impact factor: 5.386

Review 3.  Adrenal Tumors: Are Gender Aspects Relevant?

Authors:  Pier Francesco Alesina; Martin K Walz
Journal:  Visc Med       Date:  2020-01-15

4.  Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists.

Authors:  Yuichi Yoshida; Rika Yoshida; Kanako Shibuta; Yoshinori Ozeki; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Hirotaka Shibata
Journal:  J Endocr Soc       Date:  2021-02-16

5.  Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism.

Authors:  Wiebke Arlt; Katharina Lang; Alice J Sitch; Anna S Dietz; Yara Rhayem; Irina Bancos; Annette Feuchtinger; Vasileios Chortis; Lorna C Gilligan; Philippe Ludwig; Anna Riester; Evelyn Asbach; Beverly A Hughes; Donna M O'Neil; Martin Bidlingmaier; Jeremy W Tomlinson; Zaki K Hassan-Smith; D Aled Rees; Christian Adolf; Stefanie Hahner; Marcus Quinkler; Tanja Dekkers; Jaap Deinum; Michael Biehl; Brian G Keevil; Cedric Hl Shackleton; Jonathan J Deeks; Axel K Walch; Felix Beuschlein; Martin Reincke
Journal:  JCI Insight       Date:  2017-04-20

6.  Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism.

Authors:  Marilisa Citton; Giovanni Viel; Francesca Torresan; Gian Paolo Rossi; Maurizio Iacobone
Journal:  BMC Surg       Date:  2019-04-24       Impact factor: 2.102

7.  A disease-specific Quality of Life questionnaire for primary aldosteronism.

Authors:  Marieke Stientje Velema; Aline de Nooijer; Ad R M M Hermus; Henri J L M Timmers; Jacques W M Lenders; Olga Husson; Jaap Deinum
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

8.  Effects of chronically high levels of aldosterone on different cognitive dimensions: an investigation in patients with primary aldosteronism.

Authors:  Lukas Engler; Christian Adolf; Daniel A Heinrich; Anna-Katharine Brem; Anna Riester; Anna Franke; Felix Beuschlein; Martin Reincke; Axel Steiger; Heike Künzel
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

9.  Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism.

Authors:  Karl-Heinz Storbeck; Lina Schiffer; Elizabeth S Baranowski; Vasileios Chortis; Alessandro Prete; Lise Barnard; Lorna C Gilligan; Angela E Taylor; Jan Idkowiak; Wiebke Arlt; Cedric H L Shackleton
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

10.  Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study.

Authors:  Yen Kheng Tan; Yu Heng Kwan; David Choon Liang Teo; Marieke Velema; Jaap Deinum; Pei Ting Tan; Meifen Zhang; Joan Joo Ching Khoo; Wann Jia Loh; Linsey Gani; Thomas F J King; Eberta Jun Hui Tan; Shui Boon Soh; Vanessa Shu Chuan Au; Tunn Lin Tay; Lily Mae Quevedo Dacay; Keng Sin Ng; Kang Min Wong; Andrew Siang Yih Wong; Foo Cheong Ng; Tar Choon Aw; Yvonne Hui Bin Chan; Khim Leng Tong; Sheldon Shao Guang Lee; Siang Chew Chai; Troy Hai Kiat Puar
Journal:  Endocr Connect       Date:  2021-07-26       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.